Unraveling Clinical Developments in NASH

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Educational Series on NASH

Pathogenesis of NASH Moving Past the 2-Hit Hypothesis

Substrate Overload Lipotoxic Liver Injury (NASH)

Substrate Overload Lipotoxic Liver Injury (NASH) (cont)

Substrate Overload Lipotoxic Liver Injury (NASH) (cont)

Substrate Overload Lipotoxic Liver Injury (NASH) (cont)

Substrate Overload Lipotoxic Liver Injury (NASH) (cont)

Substrate Overload Lipotoxic Liver Injury (NASH) (cont)

The Fates of Fatty Acids

Targets of Therapy

Importance of Understanding Pathogenesis

CVC Phase 2b Trial CENTAUR Study

CVC Phase 2b Trial Results

ELF MOA

ELF Phase 2 Trial GOLDEN Trial

ELF Phase 2 Trial GOLDEN Trial Results

OCA Phase 2b Trial FLINT Trial

OCA Phase 2b Trial FLINT Trial Results

OCA Phase 2b Trial Pruritis and Cholesterol

Limitations of Current Phase 3 Trials in NASH Importance of Surrogate Endpoints

Selonsertib MOA

Selonsertib Phase 2 Trial Trial Design

Selonsertib Phase 2 Trial Trial Results

Assessment of Selonsertib Phase 2 Trial Results and Design

Current Treatment Strategies for NASH

Current Treatment Strategies for NASH (cont)

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)